Our findings indicate that the combination of CEACAM1, TNFSF4, GEM, CD47, VTCN1, and TANlncSig in squamous cell carcinoma can effectively stratify patients by prognosis, highlighting these immune checkpoint receptors as potential therapeutic targets against advanced lung cancer. Here, CEACAM1 is linked to lung cancer.